Infigratinib in pretreated cholangiocarcinoma with FGFR2 fusions or rearrangements

Abstract

Although they are the second leading cause of primary liver cancer after hepatocellular carcinoma, biliary tract cancers are rare tumours (excluding endemic areas in Asia), with less than six new cases per 100 000 people each year. 1 Banales JM Cardinale V Carpino G et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016; 13: 261-280 Crossref PubMed Scopus (561) Google Scholar Biliary tract cancers are classified into three subtypes on the basis of their anatomical origin: intrahepatic cholangiocarcinoma (the incidence of which is increasing in the USA and Europe), extra-hepatic cholangiocarcinoma, and gallbladder carcinoma. Prognosis for patients with biliary tract cancers is poor (5-year overall survival <20%), mainly due to late diagnosis, frequently at an advanced stage (in around 65% of patients). 1 Banales JM Cardinale V Carpino G et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016; 13: 261-280 Crossref PubMed Scopus (561) Google Scholar Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 studyInfigratinib has promising clinical activity and a manageable adverse event profile in previously treated patients with locally advanced or metastatic cholangiocarcinoma harbouring FGFR2 gene fusions or rearrangements, and so represents a potential new therapeutic option in this setting. Full-Text PDF